Bostonglobe Biogen receives patent until 2028 for Multiple Sclerosis drug Tecfidera Reuters Tue Mar 19, 2013 4:14pm EDT. (Reuters) - Biogen Idec Inc said on Tuesday it has been granted a new patent that will help protect the market exclusivity of its multiple sclerosis drug Tecfidera until 2028. The new patent covers the dosing regimen for Tecfidera ..
Read More:
Biogen receives patent until 2028 for Multiple Sclerosis drug Tecfidera -
Brak komentarzy:
Prześlij komentarz